MARKET

GILD

GILD

Gilead Sciences Inc
NASDAQ
122.74
-0.44
-0.36%
After Hours: 123.42 +0.68 +0.55% 19:50 12/31 EST
OPEN
123.24
PREV CLOSE
123.18
HIGH
123.60
LOW
122.38
VOLUME
3.15M
TURNOVER
--
52 WEEK HIGH
127.86
52 WEEK LOW
86.16
MARKET CAP
152.28B
P/E (TTM)
19.08
1D
5D
1M
3M
1Y
5Y
1D
XLV, ABT, AMGN, GILD: Large Outflows Detected at ETF
NASDAQ · 12/31/2025 17:30
What's Driving the Market Sentiment Around Gilead Sciences Inc?
Benzinga · 12/31/2025 14:01
Pfizer, GSK and other drugmakers eying U.S. price hikes for 350 medicines: report
Seeking Alpha · 12/31/2025 13:22
Stock Index Futures Slip in Weak End to a Banner Year
Barchart · 12/31/2025 05:21
Gilead Sciences CEO Daniel O’Day Reports Sale of Common Shares
Reuters · 12/30/2025 21:23
Stocks Fall Slightly in Thin Holiday Trade
Barchart · 12/30/2025 15:31
Stocks Slip as Bond Yields Rise
Barchart · 12/30/2025 10:06
Weekly Report: what happened at GILD last week (1222-1226)?
Weekly Report · 12/29/2025 09:31
More
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.

Webull offers Gilead Sciences Inc stock information, including NASDAQ: GILD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GILD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GILD stock methods without spending real money on the virtual paper trading platform.